Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 11, 2025 07:00 ET | Source: Denovo Biopharma

A Landmark Pivotal Study Applying Precision Medicine to Psychiatry with Denovo’s DB104 (liafensine) for Treatment-Resistant Depression Published in JAMA Psychiatry

A Landmark Pivotal Study Applying Precision Medicine to Psychiatry with Denovo’s DB104 for Treatment-Resistant Depression Published in JAMA Psychiatry
August 14, 2025 07:00 ET | Source: Denovo Biopharma

Denovo Biopharma LLC to Participate in Upcoming Investor Events

Denovo Biopharma LLC to Participate in Upcoming Investor Events
June 23, 2025 07:00 ET | Source: Denovo Biopharma

Denovo Biopharma LLC Enters into an Exclusive Out-License Agreement with Chuang Yi Global Asset Management Co., Ltd. for Biomarker-Guided DB104 (liafensine) in Patients with Treatment-Resistant Depression (TRD) in Taiwan

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative drugs, today announced that it has out-licensed its...
June 06, 2025 07:00 ET | Source: Denovo Biopharma

Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression

- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo’s CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104...